That weight-loss jab email in your inbox was probably against the rules
What happened
On 2 October 2026 the MHRA published its monthly record of advertising investigations. One section stands out. Nine companies offering weight-loss treatment services amended their advertising after the MHRA stepped in. The problem was how they promoted prescription-only medicines, including GLP-1 medicines - the group often described in adverts as 'weight loss injections'. UK law does not allow prescription-only medicines to be advertised to the public. That is not a technicality about wording. It is the core rule. You cannot publish an advert to the public that is likely to lead someone to use a prescription-only medicine. The breaches were found in ordinary places: promotional emails sent to members of the public, website home pages, and posters inside pharmacies. The MHRA also recorded a separate case. A clinic had promoted Kenalog, a steroid injection, as a treatment for hay fever. Kenalog is not licensed as a hay fever treatment in the UK. That advertising was also amended after MHRA action. In every case listed, the companies changed their advertising. The MHRA notes that its list relates to action taken on a particular date and is not an endorsement of a company's ongoing practices. The full list of named companies is published on GOV.UK.
Why this matters
Most people assume that if an advert appears in their inbox from a registered pharmacy, it must be allowed. That assumption is wrong, and it is worth understanding why the rule exists. Prescription-only medicines are prescription-only because a trained professional needs to decide whether they suit you. That decision depends on your weight, your other conditions, your other medicines, your history and your risks. Advertising works in the opposite direction. It creates demand first, then looks for a route to supply. When the product is a prescription medicine, that pressure lands on the consultation. A patient arrives already wanting a specific injection, and the clinical question becomes harder to ask honestly. GLP-1 medicines make this sharper. They are genuinely effective for some people, and genuinely unsuitable for others. They also carry side effects, require monitoring, and have been in short supply at times. Unsolicited marketing emails and texts naming medicines are specifically called out by the rules. If you have received one, you were on the receiving end of something that was not permitted.
What the evidence actually says
The MHRA's record is factual and limited, and it is worth not over-reading it. What it shows: nine companies providing weight-loss treatment services were the subject of advertising action in September 2026, and all amended their advertising. The breaches involved emails, website home pages and in-pharmacy posters. A tenth, separate case concerned promotion of Kenalog for hay fever. What it does not show: that the medicines involved are unsafe, that the companies acted dishonestly, or that anyone was harmed. Advertising rules can be broken by well-meaning marketing teams who do not know the law. The outcome recorded in every case is that the advertising changed. The MHRA is also explicit that appearing on the list says nothing about what a company does now. It is also fair to note that this list appears monthly. Nine cases in one month, across the four categories the MHRA publishes, suggests a steady stream of this kind of marketing rather than a one-off crackdown. If you want to check for yourself, the MHRA publishes the four category documents in full, with the company names, on GOV.UK.
Qurexa perspective
We are a pharmacy delivery service, so we are on the inside of this rule rather than commenting from outside it. Here is how we read it. A legitimate pharmacy service can tell you what it does - deliver prescriptions, support people with their medicines, answer questions. It should not be emailing you the name of a prescription medicine and inviting you to want it. That line is not difficult to hold. It just rules out the most profitable kind of marketing. We would rather say something less exciting and true: if a weight-loss medicine is right for you, that conclusion should come out of a proper consultation, with your full medical history in front of someone qualified, and with follow-up built in. If it is not right for you, a good service should be willing to say so and lose the sale. We would also gently suggest treating urgency in health marketing as a warning sign. 'Limited stock', 'offer ends Sunday' and 'start today' are sales language. There is no clinical reason for a prescription decision to be rushed.
Practical advice
If you get an unsolicited email or text naming a prescription weight-loss medicine, treat it as a red flag rather than an opportunity. You can report medicine advertising you think breaks the rules to the MHRA. Details for doing so are on the MHRA advertising pages on GOV.UK. Before using any online weight-loss service, check it is a registered pharmacy. In Great Britain, pharmacies are registered with the General Pharmaceutical Council, and you can search the register on their website. Prescribers should be registered with their own professional regulator. Expect a real consultation. That means questions about your height and weight, your medical history, your other medicines, and often a request for information from your GP. A form that only asks you to tick boxes is not a consultation. Ask what the follow-up looks like. Weight-loss medicines need monitoring, dose changes and a plan for stopping. If you already take a GLP-1 medicine and are worried after reading this, do not stop it on your own. Speak to your prescriber or pharmacist first. And if cost is the reason you are looking at a private service, it is still worth asking your GP what NHS options exist in your area.
What to know
The MHRA published its September 2026 advertising investigations on 2 October 2026. Nine companies offering weight-loss treatment services amended their advertising of prescription-only medicines, including GLP-1 'weight loss injections', after MHRA action. The breaches involved promotional emails, website home pages and in-pharmacy posters. A separate case involved a clinic promoting Kenalog as a hay fever injection, a use for which it is not licensed. UK law prohibits advertising prescription-only medicines to the public, including unsolicited emails and texts naming them. Appearing on the list does not mean a company is unsafe or that it still advertises this way. Check any online service is a registered pharmacy, expect a proper consultation, and never stop a prescribed medicine without advice. Sources: MHRA (GOV.UK), 'Advertising investigations: September 2026', 2 October 2026, https://www.gov.uk/government/publications/advertising-investigations-september-2026; MHRA (GOV.UK), 'Advertising investigations by MHRA', https://www.gov.uk/government/collections/advertising-investigations-by-mhra; General Pharmaceutical Council, 'Search the registers', https://www.pharmacyregulation.org/registers This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional.
Related articles
Four months early: 3,880 rural premises and an £8.2 million contract
On 13 October 2026, the government announced that a rural broadband project in North Oxfordshire had finished four months ahead of schedule. The work connected…
First hearing from a police cell: £17.4 million and four force areas
On 12 October 2026, the Ministry of Justice published the government's response to Lord Leveson's review of the criminal courts. The review made 180 recommendat…
Over 1,000 weak spots found, and a minister's message to AI firms
On Monday 12 October 2026, the UK government set out a package of measures aimed at protecting the country from increasingly powerful artificial intelligence.…